Author: Scarpini, Sara; Morigi, Francesca; Betti, Ludovica; Dondi, Arianna; Biagi, Carlotta; Lanari, Marcello
Title: Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice Cord-id: ljce57vu Document date: 2021_5_25
ID: ljce57vu
Snippet: Human cytomegalovirus (hCMV) is one of the most common causes of congenital infection in the post-rubella era, representing a major public health concern. Although most cases are asymptomatic in the neonatal period, congenital CMV (cCMV) disease can result in permanent impairment of cognitive development and represents the leading cause of non-genetic sensorineural hearing loss. Moreover, even if hCMV mostly causes asymptomatic or pauci-symptomatic infections in immunocompetent hosts, it may lea
Document: Human cytomegalovirus (hCMV) is one of the most common causes of congenital infection in the post-rubella era, representing a major public health concern. Although most cases are asymptomatic in the neonatal period, congenital CMV (cCMV) disease can result in permanent impairment of cognitive development and represents the leading cause of non-genetic sensorineural hearing loss. Moreover, even if hCMV mostly causes asymptomatic or pauci-symptomatic infections in immunocompetent hosts, it may lead to severe and life-threatening disease in immunocompromised patients. Since immunity reduces the severity of disease, in the last years, the development of an effective and safe hCMV vaccine has been of great interest to pharmacologic researchers. Both hCMV live vaccines—e.g., live-attenuated, chimeric, viral-based—and non-living ones—subunit, RNA-based, virus-like particles, plasmid-based DNA—have been investigated. Encouraging data are emerging from clinical trials, but a hCMV vaccine has not been licensed yet. Major difficulties in the development of a satisfactory vaccine include hCMV’s capacity to evade the immune response, unclear immune correlates for protection, low number of available animal models, and insufficient general awareness. Moreover, there is a need to determine which may be the best target populations for vaccine administration. The aim of the present paper is to examine the status of hCMV vaccines undergoing clinical trials and understand barriers limiting their development.
Search related documents:
Co phrase search for related documents- acute infection and adaptive immunity innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute infection and adequate immunity: 1
- acute infection and adjuvant vaccine: 1, 2, 3, 4, 5, 6, 7
- acute infection and adolescent female: 1, 2
- acute infection and long duration: 1, 2, 3, 4
- acute infection and long term outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute infection and long term sequelae: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
- acute infection and low efficacy: 1, 2, 3, 4
- acute infection and low igg avidity: 1
- acute infection and low minimal: 1, 2, 3, 4
- acute infection and low sensitivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute infection and low sequence: 1
- acute infection and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute infection and lymphocytic choriomeningitis virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- adaptive immunity and adjuvant vaccine: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive immunity and long last immune response: 1
- adaptive immunity and long term outcome: 1, 2
- adaptive immunity and low efficacy: 1, 2
- adaptive immunity and lupus erythematosus: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date